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Summary
Metformin, an oral hypoglycemic agent, has been used for
decades to treat type 2 diabetes mellitus. Recent studies indicate
that mice treated with metformin live longer and have fewer
manifestations of age-related chronic disease. However, the
molecular mechanisms underlying this phenotype are unknown.
Here, we show that metformin treatment increases the levels of
the microRNA-processing protein DICER1 in mice and in humans
with diabetes mellitus. Our results indicate that metformin
upregulates DICER1 through a post-transcriptional mechanism
involving the RNA-binding protein AUF1. Treatment with met-
formin altered the subcellular localization of AUF1, disrupting its
interaction with DICER1 mRNA and rendering DICER1 mRNA
stable, allowing DICER1 to accumulate. Consistent with the role
of DICER1 in the biogenesis of microRNAs, we found differential
patterns of microRNA expression in mice treated with metformin
or caloric restriction, two proven life-extending interventions.
Interestingly, several microRNAs previously associated with
senescence and aging, including miR-20a, miR-34a, miR-130a,
miR-106b, miR-125, and let-7c, were found elevated. In agree-
ment with these findings, treatment with metformin decreased
cellular senescence in several senescence models in a DICER1-
dependent manner. Metformin lowered p16 and p21 protein
levels and the abundance of inflammatory cytokines and onco-
genes that are hallmarks of the senescence-associated secretory
phenotype (SASP). These data lead us to hypothesize that
changes in DICER1 levels may be important for organismal aging
and to propose that interventions that upregulate DICER1
expression (e.g., metformin) may offer new pharmacotherapeutic
approaches for age-related disease.
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Introduction
Metformin has been used to treat type 2 diabetes mellitus since the
1950s. Metformin enhances insulin sensitivity and lowers blood glucose
levels by inhibiting gluconeogenesis in the liver. Metformin elicits these
effects by inhibiting the mitochondrial respiratory-chain complex I and
glycerophosphate dehydrogenase (mGPD) and also by activating
adenosine monophosphate-activated protein kinase (AMPK) (Foretz
et al., 2014; Madiraju et al., 2014). Activation of AMPK, in turn, leads
to a plethora of signaling cascades that regulate energy homeostasis and
metabolism (Hardie et al., 2012). However, AMPK-independent path-
ways activated by metformin have also been described (Pollak, 2012;
Foretz et al., 2014) and recent data also suggest that systemic effects of
metformin may have different mechanisms of action in different tissues
(Duca et al., 2015). Gaps in our knowledge about the mechanisms that
underlie its therapeutic effects persist.
Numerous epidemiologic studies show that in addition to its role in
modulating metabolic pathways, metformin also influences factors
associated with cancer incidence and cancer mortality among diabetics
treated with the drug (Pollak, 2012). These retrospective epidemiologic
studies have led to intensive focus on the potential use of metformin as
an anticancer therapeutic agent. Although many studies have focused
on uncovering how metformin elicits anticancer effects, the exact
mechanism of tumor inhibition remains unknown (Foretz et al., 2014).
Studies using cancer cells in culture and murine tumor xenografts have
found that metformin inhibits tumorigenesis by upregulating DICER1
(Blandino et al., 2012), a key enzyme that processes microRNAs
(miRNAs). Therefore, it is possible that upregulation of DICER1 may in
part mediate metformin’s antitumorigenic effects. In general with few
exceptions, cancer cells have decreased global miRNA expression (Lu
et al., 2005; Kumar et al., 2007), leading to the hypothesis that
upregulation of DICER1 may lead to increased miRNA expression, which
would then contribute to lowering tumorigenic activity. Consistent with
this idea, DICER1 expression is decreased in several types of human
cancers (Bahubeshi et al., 2011; Foulkes et al., 2014).
Conditional loss of mouse Dicer1 in skin or adipocytes induces DNA
damage and activates a p19Arf-p53 signaling pathway leading to
increased cellular senescence (Mudhasani et al., 2008; Mori et al.,
2012), indicating that modulation of DICER1 levels may influence aging-
related pathways. Additionally, dicer loss-of-function mutations in
Caenorhabditis elegans reduce lifespan and homeostatic stress responses
(Mori et al., 2012). We reported that miRNA levels decrease with
advancing age in human peripheral blood mononuclear cells (PBMCs)
and primate skeletal muscle, while others have found decreased levels of
miRNAs with age in mouse brain and in C. elegans (Noren Hooten et al.,
2010, 2013; Smith-Vikos & Slack, 2012; Mercken et al., 2013). Given
the conservation of miRNAs across species, and that a single miRNA can
regulate C. elegans lifespan and predict the mortality of individual
C. elegans (Smith-Vikos & Slack, 2012), it is likely that miRNAs play an
important role in regulating lifespan in humans and other species.
The fact that modulating DICER1 and miRNAs may be important for
regulating lower organismal aging and our recent findings that
metformin significantly increases the longevity of mice (Martin-Montalvo
et al., 2013) led us to examine mechanisms by which DICER1 expression
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is altered by metformin and the possible role of DICER1 in aging. As gene
expression is affected post-transcriptionally by noncoding RNAs and
RNA-binding proteins (RBPs), we hypothesized that post-transcriptional
mechanisms may play a role in modulating levels of DICER1 in response
to metformin. Previous evidence indicated that the RBP AU-rich element-
binding factor 1 (AUF1), also known as hnRNPD (heterogeneous nuclear
ribonucleoprotein D), lowers the stability of DICER1 mRNA through
binding to multiple regions in the coding region and 30-untranslated
region (UTR) of DICER1 mRNA (Abdelmohsen et al., 2012). AUF1
comprises 4 isoforms (p37, p40, p42, and p45) all of which contain two
RNA-recognition motifs (RRMs) (White et al., 2013; Yoon et al., 2014).
In general, cytoplasmic AUF1 promotes the decay of target mRNAs
(White et al., 2013). However, new data using the PAR-CLIP (photoac-
tivatable ribonucleoside-enhanced cross-linking and immunoprecipita-
tion) method indicate that AUF1 also affects mRNA translation and
enhances the stability of a subset of transcripts (Yoon et al., 2014).
Through these activities, AUF1 regulates cellular processes such as
senescence, proliferation, and stress and immune responses that impact
upon aging and age-related diseases.
Here, we explored the role of DICER1 in mice chronically treated with
metformin or dietary caloric restriction, two interventions that extend
mouse lifespan. We found higher levels of DICER1 in mice treated with
metformin or caloric restriction as well as in humans with diabetes
mellitus on metformin. In contrast, DICER1 mRNA levels decreased with
age in untreated human subjects. We present evidence that metformin
treatment prevents the interaction of the decay-promoting RBP AUF1
with DICER1 mRNA, resulting in increased expression of DICER1. Given
that metformin inhibits cellular senescence only in the presence of
DICER1, our results highlight a possible mechanism that may explain in
part the anti-aging effects of metformin and identify relevant pathways
and targets for further investigation.
Results
Age and metformin treatment alter DICER1 levels
We hypothesized that changes in DICER1 levels may contribute to the
age-associated decline in miRNAs (Noren Hooten et al., 2010). There-
fore, we examined DICER1 mRNA levels by reverse transcription (RT)
followed by real-time quantitative (q)PCR analysis from PBMCs from
young (~30 year old) and older (~64 year old) individuals and found a
significant decrease in DICER1 mRNA levels with human age (Fig. 1A;
Table 1A). In contrast, the levels of DROSHA mRNA, encoding another
key protein in miRNA biosynthesis, were not significantly different with
human age (Fig. 1A). Therefore, we focused on investigating whether
changes in DICER1 levels may explain alterations in miRNA expression
with age.
Previously, metformin was found to increase the healthspan and
longevity of mice (Martin-Montalvo et al., 2013). Given that metformin
elevates DICER1 in cultured cancer cells (Blandino et al., 2012), we
wanted to examine whether changes in DICER1 expression occur in mice
chronically treated with metformin and to compare these findings with
those of mice on dietary caloric restriction, an intervention that extends
lifespan in mice. In response to metformin and dietary caloric restriction,
there is an upregulation in Dicer1 mRNA levels in the livers of treated
mice compared with control mice on standard diet (Fig. 1B), and livers of
metformin-treated mice had higher DICER1 protein levels than control
mice (Fig. 1C).
Given that DICER1 mRNA levels decreased in human PBMCs from
older individuals compared with younger individuals (Fig. 1A, first panel)
and that DICER1 levels increased by metformin treatment in mice, we
investigated whether individuals being treated for diabetes with
metformin also had higher levels of DICER1. Individuals in the Healthy
Aging in Neighborhoods of Diversity across the Lifespan (HANDLS) study
Fig. 1 DICER1 levels are altered by human age and by metformin treatment in
mice and humans. (A) DICER1 and DROSHA mRNA levels were quantified from
PBMCs from young (~30 years) and old (~64 years) individuals (n = 14/group)
from the HANDLS study using RT–qPCR. (B) DICER1 mRNA and DICER protein (C)
levels were quantified by RT–qPCR and immunoblotting, respectively, from livers of
mice on standard diet (SD), metformin-treated (Met), or on calorie restriction (CR).
For protein levels in C, a representative immunoblot is shown and Dicer levels from
8 mice per group were quantified from immunoblots and normalized to actin. (D)
DICER1 mRNA levels were quantified from PBMCs of nondiabetics, diabetics taking
sulfonylureas, and diabetics taking metformin (n = 20/group). Demographic
information for cohorts in (A) and (D) is in Table 1. The histograms represent the
mean + SEM. *P < 0.05, **P ≤ 0.01.
Table 1 Demographic information for human cohorts used in Fig. 1
A. Age cohort Young Old
N 14 14
Age (mean (SD)) 30.1 (0.3) 64.2 (0.4)
Sex = Men (%) 6 (42.8) 6 (42.8)
Race = AA (%) 6 (42.8) 6 (42.8)
PovStat = Below (%) 6 (42.8) 5 (35.7)
BMIcut = Obese (%) 6 (42.8) 4 (28.6)
B. Diabetics cohort Nondiabetics
Diabetics taking
Sulfonylureas
Diabetics taking
Metformin
n 20 20 20
Age (mean (SD)) 49.45 (10.30) 52.15 (8.65) 50.50 (8.13)
Sex = Men (%) 7 (35.0) 7 (35.0) 7 (35.0)
Race = AA (%) 13 (65.0) 13 (65.0) 13 (65.0)
PovStat = Below (%) 7 (35.0) 9 (45.0) 6 (30.0)
BMIcut = Obese (%) 19 (95.0) 19 (95.0) 19 (95.0)
AA, African American; BMIcut, below or above obesity cut-off of ≥ 30 kg m2;
PovStat, Poverty status, above or below the 125% Poverty line as defined by the
Department of Health and Human Services in 2003.
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(Evans et al., 2010) were chosen based on the following criteria. The
participants were either euglycemic normal controls (i), diabetics treated
with sulfonylurea (ii), or diabetics treated with metformin (iii) (Table 1B).
The sulfonylurea group was added in the study because diabetic
individuals treated with metformin have increased survival compared
with nondiabetics and with diabetics on sulfonylurea (Bannister et al.,
2014). All groups were matched based on age, sex, race and body mass
index (BMI) (n = 20 per group; Table 1B). After isolation of RNA from
participant PBMCs and RT–qPCR analysis, diabetics treated with
metformin were found to have significantly higher levels of DICER1
mRNA compared with nondiabetics; diabetics taking sulfonylureas also
had higher levels of DICER1 mRNA, but this difference was not
significant (Fig. 1D).
Metformin regulates the RBP AUF1 localization and binding
to DICER1 mRNA
Given that chronic metformin treatment in mice increased DICER1 levels,
we hypothesized that metformin may alter post-transcriptional processes
thatwould affect the stability and/or turnover ofDicer1mRNA. In response
to changes in the environment, RNA-binding proteins (RBP) regulate gene
expression by affecting the turnover and/or translation of bound mRNAs
(Moore, 2005). Previous studies showed that the RBP AUF1 binds DICER1
mRNA and negatively regulates DICER1 protein levels by lowering the
stability of DICER1 mRNA (Abdelmohsen et al., 2012). Therefore, we
hypothesized that metformin may enhance DICER1 expression by altering
the binding of AUF1 to DICER1 mRNA. To test this possibility, we
performed a ribonucleoprotein immunoprecipitation (RIP) assay to exam-
ine the effect of metformin on the AUF1-DICER1 mRNA complex. While
AUF1was found to bindDICER1mRNAunder basal conditions, metformin
treatment dramatically reduced this interaction (Fig. 2A). As AUF1 binding
degrades DICER1 mRNA, these data suggest that by triggering the
dissociation ofAUF1-DICER1mRNAcomplexes,metformin treatmentmay
stabilize DICER1 mRNA. To further test this possibility, small interfering
RNAs were used to downregulate AUF1 levels in cells. Lowering AUF1
increased DICER1 mRNA and protein levels (Fig. 2B–D). DICER1 mRNA
levels further increased by metformin treatment, which may reflect an
effect on DICER1 at the transcriptional level (Fig. 2B). Conversely, AUF1
overexpression decreased DICER1 protein levels (Fig. 2E). These findings
suggest that metformin treatment enhances DICER1 expression at least in
part by dissociating AUF1 from DICER1mRNA.
The abundance of AUF1 was not altered by metformin treatment of
mice or cells in tissue culture (Fig. S1A,B); however, metformin affected
AUF1 subcellular localization. Although AUF1 was found in both the
cytoplasm and nucleus under basal conditions, by 1 h after addition of
metformin, AUF1 had redistributed to a predominantly nuclear localiza-
tion (Fig. 3A,B). This redistribution to the nucleus in response to
metformin was confirmed by fractionating cells into the nuclear and
cytoplasmic compartments in both HeLa and WI-38 cells (Figs 3C, S1D).
Given that AMPK is activated in response to metformin, we tested
whether AMPK activation is important for the effects of metformin on
AUF1 subcellular localization. Treatment with the AMPK inhibitor
Compound C blocked AUF1 redistribution to the nucleus in response
to metformin (Figs 3A, S1D), suggesting that the effects of metformin
on AUF1 localization are influenced by AMPK. Furthermore, lowering
AMPK levels using siRNA inhibited AUF1 redistribution from the
cytoplasm to the nucleus in response to metformin (Fig. 3D). This
translocation of AUF1 from the cytoplasm to the nucleus was associated
with the release of AUF1-DICER1 mRNA complex, facilitating DICER1
mRNA stabilization and translation.
Fig. 2 Metformin stabilizes DICER1 expression through modulating the binding of the RNA-binding protein AUF1. (A) Serum-starved HepG2 cells were treated with 500 lM
metformin or PBS for 1 h and ribonucleoprotein (RNP) immunoprecipitation (RIP) assays followed by RT–qPCR analysis was used to measure the enrichment of DICER1mRNA
in AUF1 immunoprecipitates. Each IP was compared to control IgG IP and normalized to GAPDH mRNA levels. (B) HeLa cells were transfected with either AUF1 or Control
(Con) siRNA and 24 h later, cells were treated with metformin for 24 h. The levels of HNRNPD mRNA (which encodes AUF1) and DICER1 mRNA were measured by RT–qPCR
analysis and normalized to GAPDH mRNA levels. (C–E) Cells were transfected with either AUF1 siRNA-1 (Qiagen), AUF1 siRNA-2 (Santa Cruz) or the indicated FLAG-tagged
plasmids were treated as in (B), and lysates were analyzed by immunoblotting to assess protein levels of DICER1, AUF1 and actin using specific antibodies. Histograms
represent the mean + SEM from three independent experiments. ***P < 0.001 or *P < 0.05 by Student’s t-test.
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The stoichiometry of the various AUF1 isoforms differed in their
subcellular localization in response to metformin. Specifically, the
localization of p45 was most affected by metformin, although p42/
p40 isoforms (typically found together as a single band) were moderately
affected as well. PAR-CLIP data showed that the p40, p42, and p45
isoforms bind to DICER1 mRNA; p45 in particular bound to multiple
regions within DICER1 mRNA (Table S1). Given this evidence, we tested
whether metformin affected AUF1 isoform binding to DICER1 mRNA.
Each FLAG-tagged AUF1 isoform was individually transfected into cells,
and RIP assays were performed in control and metformin-treated cells.
As shown (Fig. 3E), metformin treatment did not affect p37 or p40
binding to DICER1 mRNA, but it dramatically decreased DICER1 mRNA
bound to the p42 and p45 isoforms, supporting the notion that AUF1
translocation to the nucleus is associated with the dissociation of DICER1
mRNA from AUF1.
We next investigated whether AUF1 is phosphorylated in response to
metformin. Metformin treatment increased AUF1 phosphorylation as
detected using antibodies that recognize the phosphorylated
AMPK substrate motif and with phospho-serine/threonine antibodies
(Fig. 3F). Interestingly, several other proteins were prominent in AUF1
Fig. 3 Metformin induces AUF1 nuclear retention. (A) Serum-starved HeLa cells were treated with 500 lM metformin for 1 h. Cells were fixed and stained with an AUF1
antibody and DAPI. (B) AUF1 staining in the nucleus and cytoplasmwas quantified and normalized to DAPI-stained nuclei. (C) HeLa cells were pretreated with Compound C for
1 h or vehicle and were then subsequently treated with 500 lM metformin for 1 h. Cells were fractionated into cytoplasmic and nuclear fractions and analyzed by
immunoblotting with anti-AUF1, anti-HSP70, anti-Lamin B1 (nuclear marker), and anti-GAPDH antibodies (cytoplasmic marker). (D) HeLa cells were transfected with AMPK
siRNA or control and treated with metformin as described above. (E) HeLa cells transfected with individual isoforms of AUF1 were treated with or without metformin, and RIP
assays were performed to measure the enrichment of DICER1 mRNA in FLAG immunoprecipitates. Each IP was compared to control FLAG IP, normalized to GAPDH mRNA
levels, and then normalized to mock-treated cells. (F) AUF1 immunoprecipitates from HeLa cells treated with 500 lMmetformin for the indicated time points were probed with
anti-phospho-AMPK substrate, anti-phospho-serine/threonine, anti-HSP70, and anti-AUF1 antibodies. Black arrows indicate AUF1 phosphorylation, and red arrow indicates
HSP70 phosphorylation. Histograms in B and E represent the mean + SEM from three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001 by Student’s t-test.
Metformin modulates DICER and senescence, N. Noren Hooten et al. 575
Published 2016. This article is a U.S. Government work and is in the public domain in the USA. Aging Cell published by Anatomical Society and John Wiley & Sons Ltd.
immunoprecipitates, among them a ~70-kDa band. It was previously
reported that AUF1 binds to HSP70 and that HSP70 shuttles AUF1 to the
nucleus in response to heat shock (Laroia et al., 1999). Western blot
analysis of HSP70 in the AUF1 immunoprecipitated material revealed
that the AUF1-HSP70 interaction was enhanced in the presence of
metformin (Fig. 3F). Finally, HSP70 increased in the nucleus after
metformin treatment (Fig. 3C). These data suggest that AUF1 translo-
cation to the nucleus may be modulated by HSP70 binding in response
to metformin.
Metformin inhibits cellular senescence through DICER1
As the functional role of DICER1 in cells is to process miRNAs from
precursors to mature miRNAs, it is likely that changes in DICER1
expression would ultimately alter miRNA expression. To test this idea, we
analyzed global miRNA profiles using microarrays. Many miRNAs were
significantly altered after metformin treatment or calorie restriction
(Fig. 4A; Table S2). Consistent with the higher DICER1 levels in the liver
of metformin-treated mice, many miRNAs were found to be upregulated
by metformin (Figs 4A,B, S2). To assess whether the increases in mature
miRNAs were due to elevated transcription, we quantified the primary
miRNA (pri-miRNA, the initial unprocessed transcript of miRNAs)
transcripts of two miRNAs observed to be differentially expressed in
the presence of metformin, miR-130a-3p and miR-92a-3p (Fig. 4B,C). As
shown, neither pri-miR-130a nor pri-miR-92a levels were significantly
increased by metformin or CR (Fig. 4C). These data suggest that the
increase in mature miRNAs in mice treated with metformin was not
primarily a result of increased transcriptional activity.
Several of the miRNAs upregulated by metformin (miR-20a, miR-30,
miR-34a, miR-106b, miR-130a/b, let-7, miR-125) are important for
regulating cellular senescence or organismal aging (Fig. 4B). Further-
more, many of the targets of these miRNAs are important for regulating
senescence (Table S3), and some have opposite expression patterns in
response to metformin compared with senescence, suggesting that
metformin may affect lifespan by inhibiting cellular senescence. To
investigate this possibility, we examined whether metformin affects
cellular senescence in culture using several different senescence models:
WI-38 human fetal lung diploid fibroblasts, IMR-90 human skin fibrob-
lasts, and IDH4 fibroblasts. We chose doses of metformin that were
comparable to circulating drug levels of mice treated with 0.1%
metformin (~0.45 mM; 74.3 mg L1) and the therapeutic range in
humans (1.64  0.13 mg L1 to 6.57  0.61 mg L1) (Sum et al.,
1992). Metformin inhibited replicative senescence in WI-38 and IMR-90
cells (Fig. 5A,B,F). In IDH4 cells, senescence is induced by removal of
dexamethasone (dex) (Wright et al., 1989). Dex was removed, and cells
were cultured in the presence of metformin for 7 days; metformin
treatment reduced the number of SA-b-gal-positive IDH4 cells (Fig. 5C).
Additionally, we induced senescence by exposing WI-38 and IMR-90 cells
to ionizing radiation (IR). Treatment of cells with metformin delayed IR-
induced senescence, as assessed initially by SA-b-gal-positive cells
A
B
C
Fig. 4 miRNA expression changes in mice treated with metformin or caloric
restriction. (A) miRNAs were isolated from livers of mice on standard diet (SD),
metformin (Met; 0.1%), or on caloric restriction (CR). Using total liver RNA, miRNA
microarray analysis was performed. Heat map indicating miRNAs significantly
changed in any of the indicated comparisons (z ratio). (B) RNA was isolated from
livers from mice on standard diet (SD), treated with metformin (Met), or on caloric
restriction (CR). Mature miRNA (B) or pri-miRNA levels (C) were quantified by RT–
qPCR analysis. The histograms represent the mean + SEM for SD (n = 5), Met
(n = 5), and CR (n = 6). *P < 0.05 and **P < 0.01 compared with SD by Student’s
t-test.
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(Fig. 5D) and subsequently confirmed by examination of two
well-established protein markers of senescence, p16 and p21. All of
these markers of senescence were decreased by metformin treatment
(Fig. 5F).
A further hallmark trait of senescent cells is the secretion of
inflammatory cytokines, chemokines, and oncogenes (the senescence-
associated secretory phenotype or SASP) (Coppe et al., 2008). We
quantified the levels of several mRNAs encoding SASP factors in WI-38
cells, in IDH4 cells grown without dex, and WI-38 and IMR-90 cells
exposed to IR. The levels of IL6, IL8, CXCL1 (which encodes GRO-a), and
CXCL2 (which encodes GRO-b) mRNAs decreased by metformin treat-
ment (Fig. 6).
Fig. 5 Inhibition of cellular senescence by
metformin requires DICER1. Presenescent
WI-38 or IMR-90 cells were transfected
with either the indicated siRNAs or
transfected with pDEST-DICER1 and then
either treated with PBS or with 500 lM
metformin (Met) for 48 h and stained for
SA-b-gal activity (A,B,D). (C) IDH4 cells
cultured without dex were incubated with
metformin. (D) WI-38 and IMR-90 cells
exposed to ionizing radiation (IR) were
treated with metformin. SA-b-gal-positive
cells were counted and normalized to the
total number of cells. Representative phase-
contrast images from WI-38 cells from (B)
are shown, and the histograms represent
the mean + SEM from 3 independent
experiments. *P < 0.05, **P < 0.01 and
**P < 0.01 by Student’s t-test. (F) Lysates
from the indicated cell lines and treatments
were analyzed for protein levels of
senescence markers and actin for a protein
loading control.
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We next addressed whether the effects of metformin on senescence
were dependent on DICER1. SiRNA-mediated downregulation of DICER1
levels increased cellular senescence and blocked the ability of metformin
to lower the number of SA-b-gal-positive cells in both WI-38 and IMR-90
cells (Fig. 5A,B). Conversely, overexpression of DICER1 decreased cellular
senescence (Fig. 5E). To determine whether AMPK is required for the
senescence-inducing effects of metformin, we silenced AMPK levels. This
intervention blocked the metformin-mediated decrease in SA-b-gal-
positive cells, and this effect was reversed with DICER1 overexpression.
Collectively, these data indicate that metformin may reduce cellular
senescence by promoting DICER1 expression and that AMPK is impor-
tant for these effects.
Discussion
Previously, we reported that chronic metformin treatment increases both
healthspan and lifespan in mice (Martin-Montalvo et al., 2013). Here,
we have found that DICER1 levels are upregulated by metformin
treatment in both mice and humans in part through a post-transcrip-
tional mechanism involving the RBP AUF1. Upregulation of DICER1 by
metformin leads to higher levels of a subset of miRNAs important for
regulating senescence and aging-associated pathways. Furthermore,
metformin treatment inhibits cellular senescence through a DICER1-
dependent mechanism.
Our data suggest that DICER1 levels may contribute to aging.
Consistent results have been observed in a limited number of studies
that have examined the role of DICER1 in aging. A study in primary rat
cerebromicrovascular endothelial cells (CMVECs) found a decrease in
DICER1 levels with age, with concomitant reduction in miRNA expression
(Ungvari et al., 2013). Furthermore, aged mouse adipocytes also have
lower DICER1 levels (Mori et al., 2012). Here, we found that DICER1
mRNA levels decreased with age in human PBMCs, which may provide a
mechanism for lower miRNA levels we previously observed in this cell
population in the same cohort of individuals (Noren Hooten et al., 2010).
Compelling evidence suggests that alterations in DICER1 levels or
activity may be important for other age-associated diseases, especially
cancer. In general, DICER1 levels are decreased in different types of
human tumors and germline mutations in DICER1 are associated with a
rare type of childhood cancer called pleuropulmonary blastoma (PPB)
(Bahubeshi et al., 2011; Foulkes et al., 2014). Point mutations in DICER1
have also been described leading to tumor predisposition and referred to
as DICER1 syndrome (Bahubeshi et al., 2011; Foulkes et al., 2014).
However, the role of DICER1 in cancer is complicated as mouse cancer
models suggest that loss of one copy of the Dicer1 gene increases
tumorigenesis, whereas loss of both copies inhibits it, leading to the idea
that DICER1 functions as a haploinsufficient tumor suppressor
(Bahubeshi et al., 2011; Foulkes et al., 2014). These pieces of evidence
may reflect the importance of DICER1 on cell survival and/or indicate
that a subset of miRNAs is important for cancer progression. Neverthe-
less, these studies point to the importance of DICER1 and the need to
fully understand the consequences of altering DICER1 levels and/or
activity.
We found increased levels of miRNAs in livers of metformin-treated
mice, consistent with the fact that DICER1 processes precursor miRNAs
to mature miRNAs. As DICER1 also plays other important roles in the
RNA-induced silencing complex (RISC) and in RNA metabolism (Burger &
Gullerova, 2015), we cannot exclude the possibility that these other
functions of DICER1 may be altered by metformin and contribute to
metformin signaling. In addition, upregulation of DICER1 by metformin
may also be regulated, in part, at the transcriptional level (Blandino
et al., 2012); a comprehensive view of the spectrum of DICER1 functions
influenced by metformin is beyond the scope of this investigation.
By examining the miRNAs that were upregulated by metformin
treatment, we observed that several of these miRNAs have been
Fig. 6 SASP mRNA levels are decreased by
metformin. RNA was isolated from the
indicated cell lines and treatments as
detailed in Experimental procedures. mRNA
levels of the indicated genes were
quantified by RT–qPCR. IR, ionizing
radiation; (), mock-treated (+),
metformin-treated.
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implicated in regulating cellular senescence or aging (Table S3). Notably,
we found that metformin treatment upregulated miR-125, a putative
homolog of the C. elegans miRNA lin-4, which is a well-established
regulator of lifespan in worms (Boehm & Slack, 2005; Iba~nez-Ventoso
et al., 2008). Mutation of dicer decreases C. elegans longevity in
response to heat stress, an effect that can be rescued by overexpression
of lin-4 (Mori et al., 2012). Here, the increase in miR-125-5p levels
coincided with lifespan extension in mice in response to metformin
(Boehm & Slack, 2005; Martin-Montalvo et al., 2013). It will be
interesting in future studies to examine whether miR-125 has life-
extending properties, similar to those conferred to C. elegans by its
homolog lin-4.
Other miRNAs upregulated by metformin have also been linked to
aging in model systems, including miR-34. An age-associated alteration
in miR-34 occurs in the mouse and overexpression of miR-34 in
Drosophila extends lifespan (Li et al., 2011; Liu et al., 2012). miR-34
may play an important role in responding to DNA damage and also in
protecting against osteoporosis and neurodegeneration (Kato et al.,
2009; Liu et al., 2012; Krzeszinski et al., 2014). Metformin has been
shown to upregulate miR-34a in cancer cells in culture (Do et al.,
2014). In addition to miR-125 and miR-34a, compelling evidence also
suggests that other miRNAs including miR-20a, miR-30, miR-106b, miR-
130a/b, and let-7 family members are important regulators of cellular
senescence (Table S3) (Abdelmohsen & Gorospe, 2015). With advanc-
ing age, the number of senescent cells increases and contributes to
age-related physiology and pathologies (van Deursen, 2014). We
propose that one potential mechanism by which metformin increases
lifespan is through inhibition of cellular senescence. Metformin
decreases senescence in several different cell lines and senescence
model systems. We provide evidence that metformin lowers protein
levels of p16 and/or p21 and also decreases levels of IL6, IL8, CXCL1
and CXCL2 mRNAs, all encoding critical SASP factors. A previous report
found that metformin enhances cellular senescence using different cell
model systems and high doses of metformin (1–5 mM) with possible
value in cancer therapy (Cufi et al., 2012). Here, we chose a lower
range of concentrations (100–500 lM) that reflects the physiological
circulating levels of metformin in mice and in diabetic patients treated
with metformin (Sum et al., 1992).
We describe a post-transcriptional mechanism whereby metformin
treatment causes the redistribution of the RBP AUF1 from the
cytoplasm to the nucleus, associated with a disruption of its interaction
with DICER1 mRNA that causes increased DICER1 mRNA and protein
levels. Cellular glucose levels also regulate AUF1 shuttling to the
nucleus and AMPK is important for this effect (Gao et al., 2014). Here,
we found that AMPK is also important in mediating the effects of
metformin on AUF1 redistribution to the nucleus. Furthermore,
metformin increased the phosphorylation of AUF1 and enhanced
AUF1 binding to HSP70, an interaction that shuttles AUF1 to the
nucleus in response to heat-shock (Laroia et al., 1999). We found
evidence that metformin enhanced AUF1 binding to HSP70 and
increased HSP70 localization in the nucleus. Interestingly, a ~70 kDa
band that was serine–threonine-phosphorylated in AUF1 immunopre-
cipitates might represent HSP70, recently identified as a substrate of
AMPK (Schaffer et al., 2015). It has been observed that phosphoryla-
tion of AUF1 has been reported to regulate AUF1 protein stability and
binding to target mRNAs (Wilson et al., 2003; Li et al., 2013). AUF1 has
also been implicated in regulating cellular senescence and also targets
p16INK4a, a potent regulator of senescence (Guo et al., 2010; Pont
et al., 2012). It will be interesting to determine whether other AUF1
targets are also affected by metformin.
Although the actions of metformin have been extensively studied for
decades, the underlying mechanisms remain unclear. Here, we have
extended our mouse lifespan studies by showing that chronic metformin
treatment affects DICER1 levels both in mice and humans. This new
insight will hopefully aid both in identifying novel targets for develop-
ment of agents that could be important in the primary or secondary
prevention of cancer and increasing healthspan in older individuals.
Currently, the FDA is considering a clinical trial called Targeting Aging
with Metformin (TAME), which aims to assess whether metformin can
delay aging and age-related diseases. Our studies provide timely insight
into the molecular mechanisms through which metformin elicits anti-
aging effects in mice and humans.
Experimental procedures
Human study participants and mouse models
For Fig. 1A, a subcohort of young (30 years) and older (64 years)
participants from the Healthy Aging in Neighborhoods of Diversity across
the Life Span study (HANDLS) (Evans et al., 2010) were chosen for
examination of DICER1 and DROSHA mRNA levels with age. Clinical
information on this subcohort has been described previously and is also
listed in Table 1A (n = 14/group) (Noren Hooten et al., 2010) and
explained in the Supporting Information. DICER1 levels were quantified
from PBMCs by RT–qPCR analysis as described below and in Supporting
Information.
Frozen tissue from Martin-Montalvo et al. was used for the current
study (Animal protocol #: 352-TGB-2015). Livers from C57BL/6 mice on
metformin (0.1% w/w in diet), calorie restriction (60% daily food, AIN-
93G, allotment compared with ad lib animals) or standard diet (AIN-93G
diet) used for these studies were described previously (Martin-Montalvo
et al., 2013).
Global microRNA expression from livers of the same cohort of mice
(n = 5 per group) whose global gene expression profile was previously
reported (Accesssion Number: GSE40936) (Martin-Montalvo et al.,
2013). Total RNA including miRNAs was isolated using the Absolutely
RNA miRNA Kit (Agilent) and analyzed using the Agilent Mouse miRNA
Microarray 15.0. Microarray was performed and analyzed as previously
described (Noren Hooten et al., 2013). Individual miRNAs with pairwise
z-test P value ≤ 0.05, absolute value of Z ratio ≥ 1.5, with fdr ≤ 0.3
were considered significantly changed. The microRNA microarray data
can be accessed at GEO (Accession Number: GSE73393). miRNA
expression information from heat map is in Table S2.
Cell lines, reagents, and transfections
HepG2 cells were maintained in Minimal Essential Media containing
10% fetal bovine serum (FBS) and HeLa, IMR-90 and IDH4 cells were
grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 10% FBS. IDH4 cells were further supplemented with 1 lg mL1
dexamethasone (Wright et al., 1989). WI-38 human fetal lung diploid
fibroblasts (HDFs, Coriell Cell Repositories) were grown in DMEM
supplemented with 10% FBS and 1% nonessential amino acids. All
media contained penicillin/streptomycin. Metformin (Farmhispania S.A.,
Barcelona, Spain) was made fresh as a 100 mM stock solution in PBS. PBS
was used as a vehicle control in all experiments. Compound C
(Dorsomorphin) was purchased from Sigma-Aldrich, St. Louis, MO, USA.
Cells were transfected using Lipofectamine 2000 (Invitrogen,
Carlsbad, CA, USA) with siRNAs directed to AUF1 (Qiagen, Hilden,
Germany; AAGATCCTATCACAGGGCGAT), AUF1 (Santa Cruz;
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sc-37028), DICER1 (Santa Cruz Biotechnologies, Dallas, Texas, USA;
sc-40489), PRKAA1, and PRKAA2 (AMPKa1 and AMPKa2; both
SMARTpools from Dharmacon) or a control siRNA (Qiagen; All Stars
Negative Control). FLAG-tagged plasmids containing p37, p40, p42, or
p45 AUF1 isoforms were transfected together in equal concentrations
(Fig. 2E) or individually for RIP experiments. Twenty-four hours after
transfection, HeLa cells were treated with 500 lM metformin or PBS in
low serum media (0.1% FBS) for 24 h. HeLa cells were fractionated as
described in Supporting Information.
WI-38and IMR-90cellswerepretreated for 1 hwith500 lMmetformin
and then exposed to 10 Gy of ionizing radiation. Media and metformin
was changed every 48 h, and RNA, protein, and SA-b-gal staining
(described in Supporting Information) were performed 7 days after IR. To
induce senescence in IDH4 cells, dexamethasone was removed andmedia
changed to charcoal-stripped FBS with or without 500 lM metformin.
Media was changed every 48 h and after 7 days, RNA and protein were
isolated, and SA-b-gal staining was performed.
Reverse transcription (RT) followed by real-time, quantitative
(q)PCR analysis
RNA was reverse-transcribed using the QuantiMir cDNA kit (System
Biosciences, Mountain View, CA, USA) according to the manufacturer’s
instructions and real-time, quantitative (q)PCR amplification of mRNA,
rRNA, pri-microRNA, and microRNA was carried out as explained in the
Supporting Information.
Immunoprecipitation, immunoblotting, and
immunofluorescence
Mouse livers were homogenized in RIPA buffer containing protease and
phosphatase inhibitors. Lysates were centrifuged, and equal protein
concentrations of the supernatant were analyzed using SDS-PAGE. For
immunoprecipitation experiments, HeLa cells were serum-starved in
0.1% FBS-containing media for 18 h then treated for the indicated times
with 500 lM metformin or PBS. Cells were lysed in a buffer containing
TBS, 1% Triton-X100, 2 mM EDTA, and phosphatase and protease
inhibitors, clarified, and incubated with Gamma bind beads precoated
with anti-AUF1 antibodies (Cell Signaling, Danvers, MA, USA) for 1.5 h.
After extensive washing, immunoprecipitations were analyzed by SDS-
PAGE. The antibodies used for immunoblotting are described in the
Supporting Information.
AUF1 immunofluorescence in HeLa cells was analyzed as described in
Supporting Information, using a Zeiss Observer D1 microscope with an
AxioCam1Cc1 camera at a set exposure time.
Immunoprecipitation of ribonucleoprotein (RNP) complexes
HepG2 cells were starved for 18 h and then treated in serum-free media
for 1 h with 500 lM metformin or PBS, and ribonucleoprotein (RNP)
immunoprecipitation (RIP) assays were carried out as described previ-
ously (Yoon et al., 2014). To test AUF1 isoform binding to DICER1
mRNA, HeLa cells were transfected with individual plasmids encoding
FLAG-tagged p37, p40, p42, or p45 AUF isoforms. RIP analysis is
described in Supporting Information.
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Fig. S1 AUF1 protein levels and subcellular localization in response to
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